White & Case advises Azurity Pharmaceuticals, Inc. on acquisition of Slayback Pharma, LLC
1 min read
Global law firm White & Case LLP has advised Azurity Pharmaceuticals, Inc. on its acquisition of Slayback Pharma, LLC from existing investors including KKR, a leading global investment firm, and Everstone Capital.
The acquisition brings together companies with complementary strengths, enhancing Azurity's ability to realize its purpose of serving overlooked patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.
Azurity is a privately held pharmaceutical company specializing in providing innovative, high-quality medicines that serve millions of overlooked patients. Azurity supplies a large number of products to treat a wide range of medical conditions, including cardiovascular, central nervous system, endocrine, gastrointestinal, anti-infective and oncology medicines. Many of Azurity's medicines are dose-form innovations for patients with needs that are not met by other available products.
The White & Case team was led by M&A partners John Reiss, Luke Laumann and Matthew Hendy (all in New York), and included Antitrust partners Rebecca Farrington, Anna Kertesz and Kathryn Mims (all in Washington, DC); Pharmaceutical Industry Technology Transactions partner Andres Liivak (New York) and counsel Ajita Shukla (Washington, DC); Pharmaceutical Industry Intellectual Property partner Anita Varma (Boston); Debt Finance partner Sherri Snelson (New York); Tax partner Sang I. Ji, and associates Narissa Lyngen and Adriana Zhan (all in New York); and Employment, Compensation & Benefits partner Victoria Rosamond and associate Peter Shelburne (both in New York).
For more information please speak to your local media contact.